HLVX HilleVax, Inc. revenue, earnings and financials
For the quarter ended June 30, 2025, HilleVax, Inc. reported revenue of n/a, net income of −$5.27M and diluted EPS of −$0.11; for the fiscal year ended December 2024 revenue was n/a.
HLVX annual revenue and earnings
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$155M, net income −$147M (margin n/a), EPS −$3.00
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$133M, net income −$124M (margin n/a), EPS −$3.04
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$65.1M, net income −$160M (margin n/a), EPS −$5.89
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$53.4M, net income −$102M (margin n/a), EPS −$18.22
HLVX quarterly revenue and earnings
- Quarter ended Jun 30, 2025: revenue n/a, net income −$5.27M, EPS −$0.11
- Quarter ended Mar 31, 2025: revenue n/a, net income −$6.06M, EPS −$0.12
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$33.9M, EPS −$0.68
- Quarter ended Sep 30, 2024: revenue n/a, net income −$25.8M, EPS −$0.52
- Quarter ended Jun 30, 2024: revenue n/a, net income −$40.7M, EPS −$0.83
- Quarter ended Mar 31, 2024: revenue n/a, net income −$46.8M, EPS −$0.97
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$37.0M, EPS −$0.78
- Quarter ended Sep 30, 2023: revenue n/a, net income −$31.8M, EPS −$0.81
- Quarter ended Jun 30, 2023: revenue n/a, net income −$27.9M, EPS −$0.74
- Quarter ended Mar 31, 2023: revenue n/a, net income −$26.9M, EPS −$0.71
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$21.2M, EPS $6.65
- Quarter ended Sep 30, 2022: revenue n/a, net income −$16.8M, EPS −$0.45
- Quarter ended Jun 30, 2022: revenue n/a, net income −$53.9M, EPS −$2.03
- Quarter ended Mar 31, 2022: revenue n/a, net income −$67.9M, EPS −$10.06
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$37.3M, EPS −$7.53
- Quarter ended Sep 30, 2021: revenue n/a, net income −$61.9M, EPS −$10.03
- Quarter ended Jun 30, 2021: revenue n/a, net income −$1.67M, EPS −$0.34
- Quarter ended Mar 31, 2021: revenue n/a, net income −$1.55M, EPS −$0.32
HLVX cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$109M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$86.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$62.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$7.30M, share buybacks n/a
HLVX balance sheet
- Jun 30, 2025: cash $58.7M, total assets $175M, total liabilities $27.1M, shareholders' equity $148M
- Mar 31, 2025: cash $47.5M, total assets $179M, total liabilities $27.9M, shareholders' equity $151M
- Dec 31, 2024: cash $154M, total assets $193M, total liabilities $38.2M, shareholders' equity $154M
- Sep 30, 2024: cash $104M, total assets $221M, total liabilities $36.3M, shareholders' equity $184M
- Jun 30, 2024: cash $108M, total assets $277M, total liabilities $72.0M, shareholders' equity $205M
- Mar 31, 2024: cash $141M, total assets $314M, total liabilities $75.3M, shareholders' equity $239M, long-term debt $25.5M
- Dec 31, 2023: cash $217M, total assets $344M, total liabilities $78.9M, shareholders' equity $266M, long-term debt $25.2M
- Sep 30, 2023: cash $209M, total assets $367M, total liabilities $68.3M, shareholders' equity $299M, long-term debt $25.0M
Is HLVX profitable?
No. HilleVax, Inc. lost $71.1M over the last four quarters.
What is HLVX's EPS?
Diluted earnings per share over the last four quarters were −$1.43; −$0.11 in the latest quarter.